D iabetes mellitus is an established risk factor of atherosclerosis 1 and restenosis after percutaneous coronary interventions (PCI). 2 New-generation drug-eluting stents (DES) provide improved safety and efficacy when compared with balloon angioplasty, bare-metal stents, and early-generation DES, 3 including patients with diabetes mellitus. 4 In addition, advances in medical therapy including high-dose statins seem to mitigate the markedly accelerated progression of native atherosclerosis in diabetic patients. 5 Intriguingly, although diabetes mellitus has historically been considered a powerful Background-Diabetes mellitus and angiographic coronary artery disease complexity are intertwined and unfavorably affect prognosis after percutaneous coronary interventions, but their relative impact on long-term outcomes after percutaneous coronary intervention with drug-eluting stents remains controversial. This study determined drug-eluting stents outcomes in relation to diabetic status and coronary artery disease complexity as assessed by the Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score. Methods and Results-In a patient-level pooled analysis from 4 all-comers trials, 6081 patients were stratified according to diabetic status and according to the median SYNTAX score ≤11 or >11. The primary end point was major adverse cardiac events, a composite of cardiac death, myocardial infarction, and clinically indicated target lesion revascularization within 2 years. Diabetes mellitus was present in 1310 patients (22%), and new-generation drug-eluting stents were used in 4554 patients (75%). Major adverse cardiac events occurred in 173 diabetics (14.5%) and 436 nondiabetic patients (9.9%; P<0.001). In adjusted Cox regression analyses, SYNTAX score and diabetes mellitus were both associated with the primary end point (P<0.001 and P=0.028, respectively; P for interaction, 0.07). In multivariable analyses, diabetic versus nondiabetic patients had higher risks of major adverse cardiac events (hazard ratio, 1.25; 95% confidence interval, 1.03-1.53; P=0.026) and target lesion revascularization (hazard ratio, 1.54; 95% confidence interval, 1.18-2.01; P=0.002) but similar risks of cardiac death (hazard ratio, 1.41; 95% confidence interval, 0.96-2.07; P=0.08) and myocardial infarction (hazard ratio, 0.89; 95% confidence interval, 0.64-1.22; P=0.45), without significant interaction with SYNTAX score ≤11 or >11 for any of the end points. Conclusions-In this population treated with predominantly new-generation drug-eluting stents, diabetic patients were at increased risk for repeat target-lesion revascularization consistently across the spectrum of disease complexity. The SYNTAX score was an independent predictor of 2-year outcomes but did not modify the respective effect of diabetes mellitus. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00297661, NCT00389220, NCT00617084, and NCT01443104.
Diabetes, SYNTAX Score, and DES Outcomes predictor of adverse clinical outcomes after PCI, diabetic status did not emerge as a correlate of restenosis [6] [7] [8] and was not an independent predictor of mortality in an increasing number of studies in the DES era. 9, 10 The complexity of coronary artery disease (CAD) strongly affects outcomes after PCI. The Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score, a comprehensive angiographic scoring system to quantify CAD complexity, 11 can effectively risk-stratify patients undergoing PCI 12, 13 and is recommended to guide the choice between revascularization by PCI versus coronary artery bypass grafting (CABG). 14 Although both diabetic status and disease complexity adversely impact prognosis after PCI, their relative contribution to clinical outcomes in the DES era remains controversial. The SYNTAX trial showed a graded risk of repeat revascularization and mortality after PCI in diabetics across higher SYNTAX score values, 15 whereas the Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) trial reported the absence of a prognostic impact of the SYNTAX score in diabetic patients randomized to PCI with early-generation DES. 16 Adding to this conundrum, the SYNTAX score, but not diabetes mellitus, independently predicted the long-term mortality in the SYNTAX trial. 17 Moreover, a pooled analysis of DES trials identified diabetes mellitus as a correlate of repeat revascularization only in the presence of complex lesions, suggesting that DES may mitigate the vasculoproliferative cascade of diabetes mellitus when angiographically simple lesions are treated 18 ; however, by focusing only on the focal complexity of treated lesions, that analysis inherently ignored global disease complexitywhich is particularly important among diabetics who typically harbor advanced, diffuse disease.
Whether diabetes mellitus remains an independent predictor of adverse outcomes after PCI with DES, ie, outcomes are driven by diabetes mellitus per se or by higher CAD complexity in diabetic patients, is not well established. This study sought to assess the impact of diabetic status on long-term DES outcomes in relation to baseline CAD complexity as assessed by the SYNTAX score. Therefore, we analyzed a large, broadly inclusive population of patients enrolled in 4 all-comers randomized trials and treated with predominantly (75%) new-generation DES.
Methods

Patient Population
Individual patient-level data from 4 randomized clinical studies were pooled: the Sirolimus-Eluting and Paclitaxel-Eluting Stent for Coronary Revascularization (SIRTAX) trial (NCT00297661), 19 the Limus Eluted From a Durable Versus Erodable Stent Coating (LEADERS) trial (NCT00389220), 20 22 All trials had an all-comers design, were conducted between 2004 and 2013 at European institutions with the exclusive use of DES, and had data available on the SYNTAX score. [19] [20] [21] [22] Briefly, patients with either stable CAD or acute coronary syndrome were eligible if they had at least 1 lesion with a diameter stenosis ≥50% in a vessel with reference diameter of 2.25 to 4.0 mm (SIRTAX, RESOLUTE All Comers, and BIOSCIENCE trials) or 2.25 to 3.5 mm (LEADERS trial). Inclusion criteria were broad to reflect routine clinical practice. None of the trials imposed restrictions with respect to number of treated lesions, treated vessels, lesion length, or number of stents implanted. In the present analysis, we excluded patients with previous CABG and unavailable SYNTAX scores. All trials were approved by the ethics committees at each study center, and all patients provided written, informed consent.
SYNTAX Score Calculation
Angiographic variables for calculation of the SYNTAX score were prospectively collected by core laboratory analysts in the LEADERS and RESOLUTE trials and retrospectively assessed in the SIRTAX and BIOSCIENCE trials. The SYNTAX score for each patient was calculated by scoring all coronary lesions with diameter stenosis ≥50% in a vessel with reference diameter ≥1.5 mm using the previously described algorithm. 11 All angiograms were scored by 2 experienced interventional cardiologists blinded to patient data; in case of disagreement, the opinion of a third analyst was acquired and the final decision was made by consensus.
Clinical End Points and Definitions
We assessed 2-year clinical outcomes in patients categorized according to diabetic status and SYNTAX score ≤11 or >11, ie, the median value in this cohort. In an exploratory analysis, patients were categorized based on SYNTAX score ≤22 versus >22 using a clinically relevant cutoff introduced in the SYNTAX trial 15 and advocated for decision-making on revascularization by means of PCI or CABG. 14 The primary end point was major adverse cardiac events (MACE), a composite of cardiac death, nonfatal myocardial infarction (MI), and clinically indicated target lesion revascularization (TLR). The principal efficacy end point was clinically indicated TLR, defined as any repeat percutaneous or surgical intervention caused by a stenosis
WHAT IS KNOWN
• Patients with diabetes mellitus are prone to develop complex coronary atherosclerotic disease.
• Diabetes mellitus and angiographic coronary artery disease complexity unfavorably affect prognosis after percutaneous coronary interventions, but their inter-relating effect after percutaneous coronary interventions with drug-eluting stents has been controversial.
WHAT THE STUDY ADDS
• In this population undergoing percutaneous coronary interventions with predominantly new-generation drug-eluting stents, the risk of repeat target-lesion revascularization was higher for diabetic versus nondiabetic patients consistently across the spectrum of disease complexity.
• The SYNTAX score emerged as an independent predictor of long-term outcomes but did not modify the respective effect of diabetes mellitus.
• Diabetes mellitus per se, and not higher disease complexity among diabetic patients, is a driver of inferior efficacy and adverse percutaneous coronary interventions outcomes in the era of drug-eluting stents. Diabetes, SYNTAX Score, and DES Outcomes within the stent or within the 5-mm borders proximal or distal to the stent. Secondary end points included individual components of the composite end point and target-vessel revascularization (TVR), defined as any revascularization within the major coronary vessel proximal or distal to a target lesion including side branches and the target lesion itself. Cardiac death was defined as any death caused by an immediate cardiac cause, procedure-related mortality, and death of unknown cause. The definition of MI across trials is presented in Table  I in the Data Supplement. Stent thrombosis was adjudicated based on Academic Research Consortium criteria. 23 End point definitions were comparable across the trials, and pooled meta-analyses of these trials have been previously published. 24 A blinded clinical events committee independently adjudicated all adverse events for each trial.
Statistical Analyses
Continuous variables are presented as mean±SD or median with interquartile range and were compared using independent samples Student t test. Categorical variables are expressed as counts and percentages and were compared using χ 2 or Fisher exact tests as appropriate. Baseline lesion variables were analyzed using General or Generalized Linear-Mixed models, accounting for lesions nested within patients. Clinical outcomes within 2 years were expressed as counts with incidence rates computed according to Kaplan-Meier method. Cox regression analysis was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs). Adjusted HR were derived from multiple imputation estimated Cox regressions (20 data sets created using chained equations and estimates combined using Rubin rule), adjusting for baseline variables associated with the primary composite end point (age, sex, body mass index, hypercholesterolemia, renal failure defined as glomerular filtration rate <60 mL/min, history of MI, left ventricular ejection fraction, and clinical indication for index PCI, ie, stable CAD versus STEMI or non-ST-elevation acute coronary syndrome). Multiple-chained equations were used 25 to impute missing values ( Table II in the Data Supplement), using all the information of the baseline variables and the primary end point (predictive mean matching with the nearest 5 neighboring continuous variables, logistic regression for binary variables, and ordinal regression for clinical indication). In addition to SYNTAX score categories based on the median value, SYNTAX score was analyzed as a continuous variable to explore the effects of increasing SYNTAX score values on the primary end point. The effect of ln-transformed SYNTAX score was modeled using adjusted Cox's regressions, and an interaction test between diabetic status and SYNTAX score was applied. Analyses were performed with STATA version 14 (Stata Corp, College Station, TX). Differences were considered statistically significant at the 0.05 level.
Results
The present analysis included 6081 patients: 1310 diabetics (22%) and 4771 patients (78%) without medically treated diabetes mellitus ( Figure 1 ). The majority of patients (4554; 75%) received new-generation DES. Median SYNTAX score was 11 (interquartile range, 7-18) and the mean was 13.1±8.7 ( Figure 2 ). Follow-up was available in 5912 patients (97%) at 2 years.
Baseline Characteristics
Baseline characteristics are summarized in Table 1 and Table  III in the Data Supplement. Patients with diabetes mellitus were older and more commonly women, had a more advanced cardiovascular risk factor profile, and presented more frequently with stable CAD than nondiabetic patients. 
Clinical Outcomes in Relation to Diabetic Status
At 1 year, diabetic compared with nondiabetic patients had higher unadjusted, but similar adjusted risks of MACE (HR, 1.15; 95% CI, 0.93-1.42; P=0.20), TLR (HR, 1.36; 95% CI, 1.00-1.84; P=0.051), cardiac death (HR, 1.29; 95% CI, 0.81-2.05; P=0. 28) , and MI (HR, 0.89; 95% CI, 0.64-1.23; P=0.47; Figure I in the Data Supplement).
Clinical outcomes within 2 years are shown in Figure 3 . In crude analyses, diabetic patients had higher rates of the primary end point (14.5% versus 9.9%), TLR (8.6% versus 5.1%), TVR (9.8% versus 6.5%), cardiac death ( 
Two-Year Clinical Outcomes in Relation to Diabetic Status and SYNTAX Score
The rate of MACE was higher in diabetic versus nondiabetic patients with SYNTAX score ≤11 (11.8% versus 7.2%; P<0.001) and >11 (16.7% versus 12.7%; P<0.001). In multivariable analyses, there was no formal interaction (P int =0.58) for MACE between diabetic and nondiabetic patients in relation to SYNTAX score ≤11 (HR, 1.46; 95% CI, 1.06-2.03; P=0.022) and >11 (HR, 1.10; 95% CI, 0.85-1.41; P=0.48). Similarly, there was no interaction of the SYNTAX score with diabetic status on TLR (P int =0.12), TVR (P int =0.38), cardiac death (P int =0.12), MI (P int =0.10), and definite stent thrombosis (P int =0.50; Figure 3 ). Kaplan-Meier curves for MACE and TLR in relation to diabetic status and SYNTAX score ≤11 versus >11 are shown in Figure 4 .
Consistently, an exploratory analysis using SYNTAX score >22 (n=864; 14% of patients) versus ≤22 showed no interaction between the SYNTAX score category and diabetic status on MACE (P int =0.10), TLR (P int =0.43), TVR (P int =0.73), cardiac death (P int =0.99), and MI (P int =0.10; Figure III in the Data Supplement).
Analyses of MACE and TLR in relation to SYNTAX score as a continuous variable are shown in Figure 5 . In Cox regression analyses, the HRs of MACE and TLR were associated with the SYNTAX score (P<0.001 for both end points) P values comparing diabetes mellitus vs no diabetes mare derived from *Poisson regression; otherwise P values from mixed models for the per-lesion analyses, accounting for lesions nested within patients. Diabetes, SYNTAX Score, and DES Outcomes and with diabetes mellitus (P=0.028 and P=0.04, respectively) without significant interaction (Pint=0.07 and 0.17, respectively). Similar results were derived in an ancillary analysis imputing SYNTAX scores in patients who were excluded from the main analyses because of missing SYNTAX scores ( Table IV in the Data Supplement) .
Multivessel treatment at index procedure was an independent predictor of 2-year MACE (P=0.008); this association was not significant when the SYNTAX score was entered into the multivariable model (P=0.15).
Discussion
This study explored the inter-relating effects of diabetes mellitus and angiographic CAD complexity on long-term PCI outcomes in a sizable, broadly inclusive population of patients treated with predominantly new-generation DES. We found unfavorable efficacy outcomes for diabetic versus nondiabetic patients as reflected by 25% higher adjusted risk of the deviceoriented primary end point and 54% higher risk of TLR; diabetic status, however, was not associated with higher cardiac mortality or MI risk in multivariable analyses. Notably, differences in outcomes between diabetic and nondiabetic patients persisted across the spectrum of disease complexity. Although the SYNTAX score was an independent predictor of clinical outcomes, it did not modify the respective effect of diabetes mellitus throughout 2 years of follow-up. Together these findings indicate that diabetes mellitus per se, and not higher disease complexity among diabetic patients, is a driver of inferior efficacy and adverse PCI outcomes in the era of DES.
Impact of Diabetes Mellitus on PCI Outcomes
The role of diabetes mellitus in the pathobiology of native atherosclerosis and in-stent restenosis is well characterized. 26 Studies with balloon angioplasty, bare-metal stents, and earlygeneration DES consistently identified diabetes mellitus as a risk factor of mortality and repeat revascularization. 1, 2, 27 Nonetheless, growing evidence has somewhat challenged that notion by demonstrating no excess of angiographic and clinical restenosis in diabetics versus nondiabetic patients treated with DES 6-8 and by identifying diabetes mellitus as a univariate, but not as a multivariate predictor of mortality after PCI. 9, 10, 17 In the present analysis, diabetes mellitus emerged as an independent predictor of long-term MACE, a difference driven by higher rates of TLR. Although new-generation DES have shown superior efficacy and safety than earlier devices within diabetic populations, 4 in this study, repeat target-lesion revascularizations remained more frequent in diabetic patients, including a sensitivity analysis focusing on new-generation DES. The nondiffering risk of MACE in relation to diabetic status in that sensitivity analysis is a notable hypothesis-generating finding that requires definitive evaluation in prospective trials using contemporary, new-generation DES. Our finding that event rates were numerically higher in diabetic patients at 1 year ( Figure I Diabetes, SYNTAX Score, and DES Outcomes but only accrued to reach statistical significance within 2 years reflects the cumulative pathobiological sequelae of diabetes mellitus on the coronary vasculature and highlights the caveat of assessing short-term PCI outcomes in diabetic patients.
We found that diabetes mellitus was associated with cardiac death and MI in univariable, but not in multivariable analyses. Although DES did not mitigate the prorestenotic impact of diabetes mellitus in this analysis, cardiac mortality and MI (which are frequently triggered from nontarget lesions that are not treated during the index procedure 28 ) were comparable between diabetic and nondiabetic patients. The fact that the individual components of MACE were secondary end points, however, requires consideration. Although in the absence of serial angiographic assessment, this study cannot address progression of native atherosclerotic disease, these findings likely reflect the effectiveness of secondary prevention measures in improving clinical outcomes and attenuating the accelerated progression of coronary atherosclerosis 5 among diabetic patients treated with evidence-based adjunctive medical therapies.
Combined Impact of Diabetes Mellitus and Disease Complexity on 2-Year Clinical Outcomes
Previous analyses of the combined effect of diabetes mellitus and anatomic CAD complexity on PCI outcomes have led to contradictory results. The FREEDOM trial found no significant prognostic impact of the SYNTAX score on outcomes after PCI or CABG in diabetic patients 16 although the SYNTAX score only became operational during that trial. 29 In contrast, in the SYNTAX trial, adverse events increased incrementally across higher SYNTAX score tertiles, driven largely by more frequent revascularization 15 ; diabetes mellitus was not an independent predictor of long-term mortality and was therefore not included among the clinical variables of the SYNTAX score II. 17 The present analysis sought to address the relative contribution of diabetes mellitus and CAD complexity to PCI outcomes in a cohort with overall less complex disease, yet with a greater number of patients with intermediate/high (>22) SYNTAX scores (n=864) than the respective PCI subgroups of the SYNTAX and FREEDOM trials. Although SYNTAX score emerged as an independent predictor of MACE and TLR in the present analysis, event rates were consistently higher in diabetic versus nondiabetic patients across the spectrum of CAD complexity. Our finding of similar risks of MACE and TLR between diabetic patients with SYNTAX score ≤11 and nondiabetic counterparts with SYNTAX scores >11 ( Figure 4B and 4D) signifies that longterm PCI outcomes are driven by diabetic status per se and not necessarily by the higher disease complexity among diabetic The ability to risk-stratify patients who undergo myocardial revascularization has broad implications for the selection of the preferred treatment strategy (CABG versus PCI). 14 In current European guidelines, 14 PCI is an acceptable alternative to CABG in the setting of SYNTAX scores 23 to 32 in nondiabetic patients but is not advocated in diabetics with SYNTAX scores ≥23 on the basis of the SYNTAX diabetic substudy 30 and a meta-analysis of the SYNTAX and FREEDOM trials. 31 As both trials 15, 16 used early-generation DES, one may speculate that newer-generation DES might bridge the existing gap between CABG and PCI with baremetal stents or earlier DES. 32 In this study-even though there was formally no significant interaction for the primary end point in our exploratory analysis using the 22 score cutoffpoint estimates indicate higher MACE and TLR rates in diabetic versus nondiabetic patients with SYNTAX scores ≤22, but not in those with scores >22. In the absence of a CABG group, this analysis cannot address the relative value of each revascularization mode in relation to SYNTAX scores and diabetic status. Randomized ) are expected to determine whether PCI outcomes using novel devices remain inferior in diabetic patients with intermediate/high SYNTAX scores, and to define optimal prognostic cutoffs and revascularization strategies in diabetic and nondiabetic patients.
Kedhi et al 18 previously showed that TLR and TVR within one year following PCI with DES were more frequent in diabetic versus nondiabetic patients only in the presence of American College of Cardiology/American Heart Association complex target lesions, without differences when simple lesions were treated. Although the concept that DES may offset the prorestenotic impact of diabetes mellitus for local lesion recurrence in the setting of noncomplex lesion is pathobiologically plausible, that analysis did not account for disease complexity beyond the treated lesion-which is particularly important in diabetic patients who typically harbor diffuse disease. The present study provides complementary insights by assessing global CAD complexity, using an established angiographic tool for this purpose.
This study advances our understanding of the combined impact of diabetes mellitus and CAD complexity on PCI outcomes in several ways. First, in contrast to previous investigations focusing on patients with 3-vessel CAD and left main disease, 15, 16 the present analysis provides a more C and D) . Average-adjusted effect of SYNTAX score (A and C), and stratified by the presence of diabetes mellitus (red lines) or the absence of diabetes (blue lines; B and D) with P values derived from full model. Curves (solid lines) are presented with respective 95% confidence intervals (dashed lines). Patients with SYNTAX score 0 are considered to represent the reference (horizontal line set at hazard ratio=1). Diabetes, SYNTAX Score, and DES Outcomes representative view of routine clinical practice by including patients across a wide range of CAD complexity from single, simple lesions to advanced multivessel disease. Thereby, this study identifies diabetics-even with angiographically less complex disease-as higher-risk patients for long-term PCI complications. Second, unlike previous evidence focusing on early-generation DES, 15, 16 the use in this analysis of predominantly new-generation DES-which provide improved safety and efficacy when compared with early-generation DES 3,4adds new insights that require further investigation in prospective studies using exclusively new-generation DES. Third, our analysis of the SYNTAX score as a continuous variable averts the possibly confounding effect of categorization and extends the established ability of higher SYNTAX tertiles to risk-stratify patients undergoing PCI. [11] [12] [13] 
Limitations
The trials included in this post hoc analysis were not designed to evaluate outcomes in relation to diabetic status and CAD complexity; still, this is one of the largest cohorts with available SYNTAX scores to date, and it is strengthened by the broadly inclusive, all-comers design to reflect real-world practice. As in any nonrandomized comparison of treatment strategies, baseline differences were substantial; although multivariable adjustments were performed for prognostically significant variables, a possible effect of unmeasured confounders cannot be excluded. Patients with SYNTAX score >22 were under-represented in this cohort; the respective stratified analysis is, therefore, presented as a hypothesis-generating finding that requires cautious interpretation. It is unclear whether these results apply for longer follow-up durations, considering that adverse outcomes in diabetics tend to aggregate over time. Our analyses may be prone to inflated type I error because of multiple testing. The end point of any revascularization during follow-up was not available in this pooled analysis. The definition of MI was not identical but was similar across the trials; these differences are not likely to have biased our findings, as indicated also by comparable MI rates across trials ( Table V in 
Conclusions
In this sizable all-comers population treated with predominantly new-generation DES, diabetic patients were at high risk for MACE and repeat target-lesion revascularization but not for cardiac death or MI, consistently across the spectrum of disease complexity. The SYNTAX score was an independent predictor of clinical outcomes but did not modify the respective effect of diabetes mellitus within 2 years of follow-up.
